Treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of
![This figure describes management of histologic LSIL (CIN 1) preceded by... | Download Scientific Diagram This figure describes management of histologic LSIL (CIN 1) preceded by... | Download Scientific Diagram](https://www.researchgate.net/publication/340379784/figure/fig4/AS:884611643092992@1587919259191/This-figure-describes-management-of-histologic-LSIL-CIN-1-preceded-by-HSIL-cytology_Q320.jpg)
This figure describes management of histologic LSIL (CIN 1) preceded by... | Download Scientific Diagram
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
![Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI) - Bhatla - 2020 - Journal of Obstetrics Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI) - Bhatla - 2020 - Journal of Obstetrics](https://obgyn.onlinelibrary.wiley.com/cms/asset/0c7e3a69-12a7-42b8-bddb-b2f30f7c76ef/jog14168-fig-0005-m.jpg)
Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI) - Bhatla - 2020 - Journal of Obstetrics
![A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3) - Gynecologic Oncology A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3) - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8b79ddce-c852-445f-892a-f1095ab6f926/gr1_lrg.jpg)
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3) - Gynecologic Oncology
![Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis | The BMJ Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/360/bmj.k499/F1.large.jpg)
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis | The BMJ
![Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. - Abstract - Europe PMC Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3616418/bin/nihms440304f1.jpg)
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. - Abstract - Europe PMC
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
![p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix | Modern Pathology p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix | Modern Pathology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fmodpathol.2015.126/MediaObjects/41379_2016_Article_BFmodpathol2015126_Fig1_HTML.jpg)
p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix | Modern Pathology
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
![SEVEN ALGORITHMS PRIORITIZED FOR PHASE 1 OF THE GUIDELINE UPDATE - WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention - NCBI Bookshelf SEVEN ALGORITHMS PRIORITIZED FOR PHASE 1 OF THE GUIDELINE UPDATE - WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572308/bin/annex4f2.jpg)
SEVEN ALGORITHMS PRIORITIZED FOR PHASE 1 OF THE GUIDELINE UPDATE - WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention - NCBI Bookshelf
![This figure describes follow-up management that should occur after the... | Download Scientific Diagram This figure describes follow-up management that should occur after the... | Download Scientific Diagram](https://www.researchgate.net/publication/340379784/figure/fig1/AS:884611643105281@1587919259049/This-figure-describes-follow-up-management-that-should-occur-after-the-diagnostic.png)
This figure describes follow-up management that should occur after the... | Download Scientific Diagram
This figure describes management of histologic LSIL (CIN 1) in patients... | Download Scientific Diagram
![Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/be83f551-8969-4567-88f9-a7d57b7e1fff/gr1.jpg)
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
![This figure describes management of histologic LSIL (CIN 1) preceded by... | Download Scientific Diagram This figure describes management of histologic LSIL (CIN 1) preceded by... | Download Scientific Diagram](https://www.researchgate.net/publication/340379784/figure/fig4/AS:884611643092992@1587919259191/This-figure-describes-management-of-histologic-LSIL-CIN-1-preceded-by-HSIL-cytology.png)